Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 8/20 | 0.61 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699684 | 0.91 | KCNN4 (0.74) | KCNN4PDE2AEPHX2CACNA1HDRD2 | |
| SCHEMBL22470161 | 0.87 | KCNN4 (0.59) | KCNN4CYP3A4SCN9ADRD2 | |
| SCHEMBL22470516 | 0.84 | KCNN4 (0.81) | KCNN4PDE2AEPHX2CACNA1HIDO1 | |
| SCHEMBL22470490 | 0.80 | KCNN4 (0.45) | KCNN4 | |
| SCHEMBL22470505 | 0.80 | CCR2 (0.39) | KCNN4CYP3A4SCN9ADRD2 | |
| SCHEMBL22470117 | 0.79 | DRD2 (0.36) | KCNN4DRD2 | |
| SCHEMBL29356882 | 0.79 | KCNN4 (0.48) | KCNN4PDE2AEPHX2DRD2AAK1 | |
| SCHEMBL29353607 | 0.79 | KCNN4 (0.72) | KCNN4DRD2AAK1 | |
| SCHEMBL22470396 | 0.78 | CTSB (0.38) | KCNN4AAK1 | |
| SCHEMBL29354486 | 0.77 | KCNN4 (0.55) | KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006289-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2024-06-11 | — | — | US | disclosed |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-06-02 | — | — | US | disclosed |
| EP-3941903-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020193419-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885PDE2A 730/4885CYP3A4 4054/4885 |
| US-12006289-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885PDE2A 999/4885CYP3A4 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.